pregnan-3-ol-20-one | 4406-35-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: pregnan-3-ol-20-one
• 英文别名: pregnanolone；3-Hydroxypregnan-20-one；1-[(8R,9S,10S,13S,14S,17S)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethanone
• CAS: 4406-35-3
• 化学式: C₂₁H₃₄O₂
• 分子量: 318.5
• InChiKey: AURFZBICLPNKBZ-SRJHXTLLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  23
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

ADMET

毒理性

• 在妊娠和哺乳期间的影响

◉ 母乳喂养期间使用总结：由于brexanolone在乳汁中含量较低且口服生物利用度低，预计brexanolone不会对哺乳婴儿造成任何不良反应。如果母亲需要使用brexanolone，这并不是停止哺乳的理由。由于在brexanolone输注过程中可能会出现过度镇静或突然失去意识的情况，建议患者在输注过程中为任何在场的儿童提供单独的护理者。 ◉ 对哺乳婴儿的影响：截至修订日期，没有找到相关的已发布信息。 ◉ 对泌乳和乳汁的影响：在一项针对12名健康女性进行的60小时brexanolone输注研究中，根据制造商的报告，没有关于对乳汁产生影响的报道。

◉ Summary of Use during Lactation:Because of the low amounts of brexanolone in milk and low oral bioavailability, brexanolone would not be expected to cause any adverse effects in breastfed infants. If brexanolone is required by the mother, it is not a reason to discontinue breastfeeding. Because excessive sedation or sudden loss of consciousness can occur during brexanolone infusion, it is suggested that patients provide a separate caregiver for any child who is present during the infusion. ◉ Effects in Breastfed Infants:Relevant published information was not found as of the revision date. ◉ Effects on Lactation and Breastmilk:In a study of 12 healthy women given a 60-hour infusion of brexanolone, there were no reports of effects on milk production according to the manufacturer.

来源:Drugs and Lactation Database (LactMed)

反应信息

• 作为产物：
  描述：

  黄体酮 在 Hortaea werneckii B-763 at late logarithmic and stationary growth phase 作用下， 以 YNB growth medium 、 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 生成 pregnan-3-ol-20-one 、 别孕甾烷-3,20-二醇 、 20 beta-二氢黄体酮 、 睾酮 、 氢化黄体酮 、 雄烯二酮 、 醋酸睾酮
  参考文献：
  名称：

  Aspects of the progesterone response in Hortaea werneckii: Steroid detoxification, protein induction and remodelling of the cell wall

  摘要：

  Progesterone in sublethal concentrations temporarily inhibits growth of Hortaea werneckii. This study investigates some of the compensatory mechanisms which are activated in the presence of progesterone and are most probably contributing to escape from growth inhibition. These mechanisms lead on the one hand to progesterone biotransformation/detoxification but, on the other, are suggested to increase the resistance of H. werneckii to the steroid. Biotransformation can detoxify progesterone efficiently in the early logarithmic phase, with mostly inducible steroid transforming enzymes, while progesterone biotransformation/detoxification in the late logarithmic and stationary phases of growth is not very efficient. The relative contribution of constitutive steroid transforming enzymes to progesterone biotransformation is increased in these latter phases of growth. In the presence of progesterone, activation of the cell wall integrity pathway is suggested by the overexpression of Pck2 which was detected in the stationary as well as the logarithmic phase of growth of the yeast. Progesterone treated H. werneckii cells were found to be more resistant to cell lysis than mock treated cells, indicating for the first time changes in the yeast cell wall as a result of treatment with progesterone. (C) 2008 Elsevier Inc. All rights reserved.

  DOI：

  10.1016/j.steroids.2008.08.004

文献信息

• NEW STEROIDS HAVING INCREASED WATER SOLUBILITY AND RESISTANCE AGAINST METABOLISM, AND METHODS FOR THEIR PRODUCTION
  申请人：BACKSTROM Torbjorn

  公开号：US20080119416A1

  公开（公告）日：2008-05-22

  Steroid compounds having increased resistance against metabolism and increased water solubility are disclosed, together with methods for their production. These substances are suitable for the manufacture of pharmaceuticals for the treatment of steroid related or steroid induced CNS disorders and for use in methods of prevention, alleviation or treatment of such disorders.

  揭示了具有增加代谢抵抗力和增加水溶性的类固醇化合物，以及它们的生产方法。这些物质适用于制造用于治疗与类固醇相关或类固醇诱导的中枢神经系统疾病的药物，并用于预防、缓解或治疗此类疾病的方法。
• [EN] LIPID PRODRUGS OF PREGNANE NEUROSTEROIDS AND USES THEREOF<br/>[FR] PROMÉDICAMENTS LIPIDIQUES DE NEUROSTÉROÏDES DE PRÉGNANE ET LEURS UTILISATIONS
  申请人：PURETECH HEALTH LLC

  公开号：WO2020028787A1

  公开（公告）日：2020-02-06

  The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.

  本发明提供了淋巴系统定向脂质前药，以及其制药组合物、生产这种前药和组合物的方法，以及改善作为脂质前药一部分的治疗剂的生物利用度或其他性质的方法。本发明还提供了治疗疾病、紊乱或症状的方法，包括向需要的患者施用所述的脂质前药或其制药组合物。
• Nitric Oxide Releasing Prodrugs of Therapeutic Agents
  申请人：SATYAM Apparao

  公开号：US20110263526A1

  公开（公告）日：2011-10-27

  The present invention relates to nitric oxide releasing prodrugs of known drugs or therapeutic agents which are represented herein as compounds of formula (I) wherein the drugs or therapeutic agents contain one or more functional groups independently selected from a carboxylic acid, an amino, a hydroxyl and a sulfhydryl group. The invention also relates to processes for the preparation of the nitric oxide releasing prodrugs (the compounds of formula (I)), to pharmaceutical compositions containing them and to methods of using the prodrugs.

  本发明涉及已知药物或治疗剂的一氧化氮释放前药，其在此处表示为式(I)的化合物，其中药物或治疗剂包含一个或多个功能基团，独立地选自羧酸、氨基、羟基和巯基。该发明还涉及制备一氧化氮释放前药（式(I)的化合物）的方法，含有它们的药物组合物以及使用这些前药的方法。
• 1H-Pyrimido[4,5-b]indole derivatives, their preparation and therapeutic use
  申请人：Froissant Jacques

  公开号：US20080125410A1

  公开（公告）日：2008-05-29

  The invention concerns compounds of general formula (I): Wherein n, X, Y, R 1 and R 2 are as defined herein. The invention also concerns a method for preparing the compounds and their therapeutic use.

  这项发明涉及一般式(I)的化合物： 其中n、X、Y、R1和R2如本文所定义。该发明还涉及制备这些化合物以及它们的治疗用途的方法。
• STEROIDE ANIONIC COMPOUNDS, METHOD OF THEIR PRODUCTION, USAGE AND PHARMACEUTICAL PREPARATION INVOLVING THEM
  申请人：Chodounska Hana

  公开号：US20120071453A1

  公开（公告）日：2012-03-22

  A compound with general formula I for treatment of various diseases of the central nervous system, in treatment of neuropsychiatric disorders related to imbalance of glutamatergic neurotransmitter system, ischemic damage of CNS, neurodegenerative changes and disorders of CNS, affective disorders, depression, PTSD and other diseases related to stress, anxiety, schizophrenia and psychotic disorders, pain, addictions, multiple sclerosis, epilepsy and gliomas.

  一种通用化合物，用于治疗中枢神经系统的各种疾病，治疗与谷氨酸能神经递质系统失衡相关的神经精神障碍，中枢神经系统的缺血性损伤，神经退行性变化和中枢神经系统的疾病，情感障碍，抑郁症，创伤后应激障碍以及与压力、焦虑、精神分裂症和精神障碍、疼痛、成瘾、多发性硬化症、癫痫和胶质瘤相关的其他疾病。